Wittycell S.A.S.

Wittycell S.A.S. (Wittycell) is a privately held biotechnology company. It is principally engaged in the development of therapeutic and prophylactic vaccine adjuvants in the areas of oncology and infectious disease based on its two proprietary technology platforms namely, NKT adjuvant platform and cell adjuvant platform. Wittycell is primarily focused on developing innovative adjuvants, which activate the immune system to fight against infectious diseases and cancer. The product pipeline of the company includes immuno-modulator adjuvants for therapeutic and prophylactic vaccines against cancer and infectious diseases and antigen delivery adjuvants for therapeutic vaccine against cancer. The company is headquartered in Reims, France.

Street: 
8, Bis rue Gabriel Voisin
City: 
Reims
Postcode: 
51100
Federal State : 
France
WebSite: 
www.wittycell.com

Company Index Score

Current Index Score Historical Index Score
  • Wittycell S.A.S. currently scores 50 % in the index.
  • Wittycell S.A.S. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Wittycell S.A.S. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets